Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-12-20
2010-10-26
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S414000, C544S376000, C548S453000
Reexamination Certificate
active
07820675
ABSTRACT:
The present invention relates to compounds of formula (I):whereinP, R3, W1, and W2are as described herein, to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds for the preparation of a medicament against 5-HT6receptor-related disorders.
REFERENCES:
patent: 5464863 (1995-11-01), Nagamine et al.
patent: 5858995 (1999-01-01), Kawai et al.
patent: 6191141 (2001-02-01), Edwards et al.
patent: 2006/0074076 (2006-04-01), Termin et al.
patent: 2006/0293361 (2006-12-01), Caldirola et al.
patent: 0 701 819 (1996-03-01), None
patent: 0 815 861 (1998-01-01), None
patent: WO 98/27081 (1998-06-01), None
patent: WO 99/02502 (1999-01-01), None
patent: WO 99/37623 (1999-07-01), None
patent: WO 99/42465 (1999-08-01), None
patent: WO 00/34242 (2000-06-01), None
patent: WO 01/32646 (2001-05-01), None
patent: WO 02/098857 (2002-12-01), None
patent: WO 02/100822 (2002-12-01), None
patent: WO 03/013510 (2003-02-01), None
patent: WO 03/072198 (2003-09-01), None
patent: WO 04/000828 (2003-12-01), None
Bentley et al., “5-HT6Antisense Oligonucleotide I.C.V. Affects Rat Performance in the Water Maze and Feeding”,Journal of Psychopharmacology, 11(3):255 (1997).
Bentley et al., “Effect of the 5-HT6 Antagonist, Ro 4-6790 on Food Consumption in Rats Trained to a Fixed Feeding Regime”,British Journal of Pharmacology, 126:66P (1999).
Isaac et al., “6-bicyclopiperazinyl-1-arylsulfonylindoles and 6-Bicyclopiperidinyl-1-arylsulfonylindoles Derivatives as Novel, Potent, and Selective 5-HT6Receptor Antagonists”,Bioorganic&Medicinal Chemistry Letters, 10:1719-1721 (2000).
Pullagurla et al., “N1-Benzenesulfonylgramine andN1-Benzenesulfonylskatole: Novel 5-HT6Receptor Ligand Templates”,Bioorganic&Medicinal Chemistry Letters, 13:3355-3359 (2003).
Ruat et al., “A Novel Rat Serotonin (5-HT6) Receptor: Molecular Cloning, Localization and Stimulation of cAMP Accumulation”,Biochemical and Biophysical Research Communications, 193(1):268-276 (1993).
Sebben et al., “5-HT6receptors positively coupled to adenylyl cyclase in striatal neurones in culture”,Neuro Report, 5(18):2553-2557 (1994).
Slassi et al., “Recent progress in 5-HT6receptor antagonists for the treatment of CNS diseases”,Expert Opinion Therapeutic Patents, 12(4):513-527 (2002).
Woolley et al., “A role for 5-HT6receptors in retention of spatial learning in the Morris water maze”,Neuropharmacology, 41:210-219 (2001).
Bentley et al., “Effect of the 5-HT6Antagonist, Ro 04-6790 on Food Consumption in Rats Trained to a Fixed Feeding Regime”,British Journal of Pharmacology, 126 (1999): suppl.
Bourson et al., “Involvement of HT6Receptors in Nigro-Striatal Function in Rodents”,British Journal of Pharmacology, 125:1562-1566 (1998).
Dawson et al., “Selective Enhancement of Glutamatergic Neurotransmission in the Frontal Cortex and Dorsal Hippocampus by antagonism of the 5-HT6Receptor”,Monitoring Molecules in Neuroscience, pp. 318-319, Jun. 16-19, 2001.
Dawson et al., “The 5-HT6Receptor Antagonist SB-271046 Selectively Enhances Excitatory Neurotransmission in the Rat Frontal Cortex and Hippocampus”,Neuropsychopharmacology, 25(5)P:662-668 (2001).
Dawson et al., “Potentiation of Amphetamine-Induced Changes in Dopamine and 5-HT by a 5-HT6Receptor Antagonist”,Brain Research Bulletin, 59(6):513-521 (2003).
Foley et al., “The 5-HT6Receptor Antagonist SB-271045 Reverses Scopolamine-Disrupted Consolidation of a Passive Avoidance Task and Ameliorates Spatial Task Deficits in Aged Rats”,Neuropsychopharmacology, 29:93-100 (2004).
Frantz et al., “5-HT6Receptor Antagonism Potentiates the Behavioral and Neurochemical Effects of Amphetamine but not Cocaine”,Neuropharmacology, 42:170-180 (2002).
Lacroix et al., “5-HT6Receptor Antagonist SB-271046 Enhances Extracellular Levels of Monoamines in the Rat Medial Prefrontal Cortex”,Synapse, 51:158-164 (2004).
Matsumoto et al., “Characterization of Endogenous Serotonin-Mediated Regulation of Dopamine Release in Rat Prefrontal Cortex”,European Journal of Pharmacology, 383:39-48 (1999).
Meneses, Role of 5-HT6Receptors in Memory Formation,Drug News&Perspectives, 14(7):396-400 (2001).
Meneses, “Effects of the 5-HT6Receptor Antagonist Ro 4-6790 on Learning Consolidation”,Behavioural Brain Research, 118:107-110 (2001).
Minabe et al., “Effect of the Acute and Chronic Administration of the Selective 5-HT6Receptor Antagonist SB-271046 on the Activity of Midbrain Dopamine Neurons in Rats: In Vivo Electrophysiological Study”,Synapse, 52:20-28 (2004).
Otano et al., “Anxiogenic-Like Effects and Reduced Stereological Counting of Immunolabelled 5-Hydroxytryptamine6Receptos in Rat Nucleus Accumbens by Antisense Oligonucleotides”,Neuroscience, 92(3):1001-1009 (1999).
Riemer et al., “Influence of the 5-HT6Receptor on Acetylcholine Release in the Cortex: Pharmacological Characterization of 4-(2-Bromo-6-pyrrolidine-1-ylpyridine-4-sulfonyl)phenylamine, a Potent and Selective 5-HT6Receptor Antagonist”,J. Med. Chem., 46:1273-1276 (2003).
Roberts et al., “The Distribution of 5-HT6Receptors in Rat Brain: An Autoradiographic Binding Study Using the Radiolabelled 5-HT6Receptor Antagonist [125I]SB-258585”,Brain Research, 934:49-57 (2002).
Rogers et al., “5-HT6Receptor Antagonists Enhance Retention of a Water Maze Task in the Rat”,Psychopharmacology, 158:114-119 (2001).
Shirazi-Southall et al., “Effects of Typical and Atypical Antipsychotics and Receptor Selective Compounds on Acetylcholine Efflux in the Hippocampus of the Rat”,Neuropsychopharmacology, 26(5):583-594 (2002).
Sleight et al.,Brit. J. Pharmacol., (1998) 124, 556-562.
Tsai et al., “Association Analysis of the 5-HT6Receptor Polymorphism C267T in Alzheimer's Disease”,Neuroscience Letters, 276:138-139 (1999).
Wesolowska et al., “Anxiolytic-like and Antidepressant-like Effects Producted by the Selective 5-HT6Receptor Antagonist SB-258585 after Intrahippocampal Administration to Rats,”Behavioural Pharmacology18:439-446, (2007).
Wesokowska et al., “Effects of the brain-penetrant and Selective 5-HT6Receptor Antagonist SB-399885 in Animal Models of Anxiety and Depression,”NeuroPharmacology, 52:1274-1283 (2007).
Woolley et al., “Reversal of a Cholinergic-Induced Deficit in a Rodent Model of Recognition Memory by the Selective 5-HT6Receptor Antagonist, Ro 04-6790”,Psychopharmacology, 170:358-367 (2003).
Woolley et al., “5-HT6Receptors”,Current Drug Targets—CNS&Neurological Disorders, 3:59-79 (2004).
Brandt Peter
Johansson Gary
Nilsson Björn M.
Biovitrum AB
Coleman Brenda L.
Fish & Richardson P.C.
Wilson James O
LandOfFree
Benzofuran compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzofuran compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzofuran compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4168433